NO163148B - PROCEDURE FOR PLANNING A SEALING SYSTEM ON A OFFSHOREBORE PLATFORM. - Google Patents
PROCEDURE FOR PLANNING A SEALING SYSTEM ON A OFFSHOREBORE PLATFORM. Download PDFInfo
- Publication number
- NO163148B NO163148B NO822594A NO822594A NO163148B NO 163148 B NO163148 B NO 163148B NO 822594 A NO822594 A NO 822594A NO 822594 A NO822594 A NO 822594A NO 163148 B NO163148 B NO 163148B
- Authority
- NO
- Norway
- Prior art keywords
- halogen
- lower alkyl
- alkyl
- alkanoylamido
- general formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000007789 sealing Methods 0.000 title 1
- -1 biphenylyl Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000002905 alkanoylamido group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 239000008188 pellet Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MWVDFDGGDKEGKD-UHFFFAOYSA-N CC(C)(C)C1=C2C(OC(C)=O)=C(C)N(C(C(C=C3)=CC=C3Cl)=O)C2=CC=C1OC Chemical compound CC(C)(C)C1=C2C(OC(C)=O)=C(C)N(C(C(C=C3)=CC=C3Cl)=O)C2=CC=C1OC MWVDFDGGDKEGKD-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- LRYCNMNIHFEIEH-UHFFFAOYSA-M N1C=C(C2=CC=CC=C12)C(C(=O)[O-])O.[Na+] Chemical compound N1C=C(C2=CC=CC=C12)C(C(=O)[O-])O.[Na+] LRYCNMNIHFEIEH-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- JDNRBNRROYRSAG-UHFFFAOYSA-N tert-butyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC(C)(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JDNRBNRROYRSAG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B3/00—Hulls characterised by their structure or component parts
- B63B3/14—Hull parts
- B63B3/68—Panellings; Linings, e.g. for insulating purposes
-
- E—FIXED CONSTRUCTIONS
- E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
- E02B—HYDRAULIC ENGINEERING
- E02B17/00—Artificial islands mounted on piles or like supports, e.g. platforms on raisable legs or offshore constructions; Construction methods therefor
- E02B17/0008—Methods for grouting offshore structures; apparatus therefor
-
- E—FIXED CONSTRUCTIONS
- E21—EARTH OR ROCK DRILLING; MINING
- E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
- E21B35/00—Methods or apparatus for preventing or extinguishing fires
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Life Sciences & Earth Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Geology (AREA)
- Mining & Mineral Resources (AREA)
- Geochemistry & Mineralogy (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Combustion & Propulsion (AREA)
- Fluid Mechanics (AREA)
- Ocean & Marine Engineering (AREA)
- Environmental & Geological Engineering (AREA)
- Civil Engineering (AREA)
- Structural Engineering (AREA)
- Building Environments (AREA)
- Revetment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte ved fremstilling av substituerte 3-indolyl-eddiksyrer. Process for the production of substituted 3-indolyl acetic acids.
Foreliggende oppfinnelse angår en ny fremgangsmåte ved fremstilling av substituerte 3-indolyl-eddiksyrer med den generelle formel: The present invention relates to a new process for the production of substituted 3-indolyl acetic acids with the general formula:
hvor where
er fenyl, bifenylyl eller nafthyl som kan være substituert is phenyl, biphenylyl or naphthyl which may be substituted
med hydroxyl, lavere alkyl, lavere alkoxy, carbo-lavere alkoxy, lavere.alkanoyl, .lavere alkanoyloxy, fenyl, fenoxy, benzyl, benzyloxy, benzoyl, amino, mcno- eller di-lavere alkylamino, lavere alkanoylamido, N,N-di-(lavere alkyl)-earboxamido, .aminomethyl,' cyano, halogen, halogen-lavere alkyl, halogen-lavere alkoxy, halogen-lavere alkanoyl', mercapto, lavere elkylthio, halogen-lavere alkylthio, fenylthio, benzyl • thio, benzoylthio, lavere alkylsulfonyl, lavere alkylsulfinyl eller di-(lavere alkyl)-sulfamoyl, with hydroxyl, lower alkyl, lower alkoxy, carbo-lower alkoxy, lower.alkanoyl, .lower alkanoyloxy, phenyl, phenoxy, benzyl, benzyloxy, benzoyl, amino, mcno- or di-lower alkylamino, lower alkanoylamido, N,N-di -(lower alkyl)-earboxamido, .aminomethyl,' cyano, halogen, halogen-lower alkyl, halogen-lower alkoxy, halogen-lower alkanoyl', mercapto, lower alkylthio, halogen-lower alkylthio, phenylthio, benzyl • thio, benzoylthio, lower alkylsulfonyl, lower alkylsulfinyl or di-(lower alkyl)sulfamoyl,
PL-, er hydrogen eller lavere alkyl, og PL-, is hydrogen or lower alkyl, and
R,j er hydrogen, hydroxyl, lavere alkyl, lavere alkenyl, lavere alkoxy, amino, monolavere-alkylamino, di-lavere alkylsmino, bis-hydroxyethylamino, lavere alkanoylamido, aminomethyl, N-lavere alkyl-lavere alkanoylamido, di-lavere alkylaminomethyl, halogen, cyano, di-lavere alkylsulfamoyl, morfolino, N-methylpiperazinyl, N-pyrrolidyl eller N-åzacyclbpropyl., R,j is hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, amino, monolower-alkylamino, di-lower alkylsmino, bis-hydroxyethylamino, lower alkanoylamido, aminomethyl, N-lower alkyl-lower alkanoylamido, di-lower alkylaminomethyl, halogen, cyano, di-lower alkylsulfamoyl, morpholino, N-methylpiperazinyl, N-pyrrolidyl or N-azacyclbpropyl.,
Et meget viktig' trekk ved fremgangsmåteforbindelsene er nærvær av en av de angitte aroylgrupper bundet til nitrogenatomet i 1-stillingeri x indolet. A very important feature of the process compounds is the presence of one of the indicated aroyl groups bound to the nitrogen atom in the 1-position of the indole.
I de foretrukne fremgangsmåteprodukter er lavere alkoxy, fortrinnsvis methoxy, eller di-lavere alkylamino, fortrinnsvis dimethylamino. In the preferred process products are lower alkoxy, preferably methoxy, or lower alkylamino, preferably dimethylamino.
Saltene av disse l-aroyl-3-indolyl-eddiksyrer kan erholdes ved at man behandler den frie syre med base under milde betingelser. På denne måte kan man fremstille alkalimetallsalter såsom natrium-og kalium-, aluminium- eller magnesium-salter, eller salter av jordalkalimetaller, eksempelvis barium- og calciumsalter. The salts of these 1-aroyl-3-indolyl-acetic acids can be obtained by treating the free acid with a base under mild conditions. In this way, one can prepare alkali metal salts such as sodium and potassium, aluminum or magnesium salts, or salts of alkaline earth metals, for example barium and calcium salts.
Det er kjent fra Journal of Organic Chemistry 2Q, side 1177, It is known from the Journal of Organic Chemistry 2Q, page 1177,
å redusere natrium-3-indolylglyoxylat katalytisk under dannelse av 70% natrium-3-indoiylglycolat og 10% 3-indolyleddiksyre. to catalytically reduce sodium 3-indolylglyoxylate to form 70% sodium 3-indolylglycolate and 10% 3-indolylacetic acid.
Det er videre fra belgisk patent nr. 615-395 kjent at 1-acyl-3-indolyl-eddiksyrebenzylestere kan hydrogenolyseres uten angrep på 1-acylgruppen. It is further known from Belgian patent no. 615-395 that 1-acyl-3-indolyl-acetic acid benzyl esters can be hydrogenolysed without attack on the 1-acyl group.
Det kan imidlertid ut fra disse reaksjoner ikke trekkes noen slutninger angående reaksjonsbetingelsene som er nodvendige for å gjennomfore trinn. 1 av foreliggende fremgangsmåte. However, no conclusions can be drawn from these reactions regarding the reaction conditions that are necessary to carry out steps. 1 of the present method.
Fremgangsmåteforbindelsene som er omtalt ovenfor, har i hoy grad anti-inflammatorisk aktivitet og kan brukes til å hindre og hemme dannelse av granulomavev. Enkelte av dem har denne aktivitet i sterk grad og er av verdi ved behandling av arthritis og dermato-logiske sykdommer og lignende tilstander som reagerer på behandling med anti-inflammatoriske midler. Dertil har fremgangsmåteproduktene i betydelig grad antipyretisk aktivitet. For disse formål blir de normalt anvendt oralt i form av tabletter eller kapsler, og den optimale dose avhenger selvsagt av den spesielle forbindelse som brukes og av infeksjonens art og grad. Skjont de optimale mengder av disse forbindelser vil avhenge av den forbindelse som anvendes, The method compounds discussed above have a high degree of anti-inflammatory activity and can be used to prevent and inhibit the formation of granuloma tissue. Some of them have this activity to a strong degree and are of value in the treatment of arthritis and dermatological diseases and similar conditions that respond to treatment with anti-inflammatory agents. In addition, the process products have antipyretic activity to a considerable extent. For these purposes, they are normally used orally in the form of tablets or capsules, and the optimal dose obviously depends on the particular compound used and on the nature and degree of the infection. Although the optimal amounts of these compounds will depend on the compound used,
og av den spesielle sykdomstilstand som skal behandles, kan de foretrukne forbindelser oralt brukes i mengder innen området 1,0 - 200 mg pr. dag i tilfelle av arthritis, avhengig av den spesielle forbind-elses aktivitet og pasientens reaksjonsfolsomhet. and of the particular disease state to be treated, the preferred compounds can be orally used in amounts within the range of 1.0 - 200 mg per day in the case of arthritis, depending on the activity of the particular compound and the patient's responsiveness.
I henhold til.oppfinnelsen fremstilles forbindelsene av formel I ved at en forbindelse med den generelle formel: hvor R-^ og R^ er som ovenfor angitt, og R'^ er R^ eller nitro, hydrogeneres ved et trykk på ca. lh kg/cm^, i nærvær av en palladium-katalysator i et inert opplosningsmiddel som dioxan, og at den dannede forbindelse med den generelle formel: According to the invention, the compounds of formula I are prepared by hydrogenating a compound of the general formula: where R-^ and R^ are as indicated above, and R'^ is R^ or nitro, at a pressure of approx. lh kg/cm^, in the presence of a palladium catalyst in an inert solvent such as dioxane, and that it formed a compound of the general formula:
hvor R-p Rp og R ^ er som ovenfor angitt, oppvarmes i et inert opplosningsmiddel i nærvær av en katalytisk virkende mengde av en sterk syre, og at den således dannede syre, om onskes, overfores til et salt derav på i og for seg kjent vis. where R-p Rp and R ^ are as indicated above, is heated in an inert solvent in the presence of a catalytically effective amount of a strong acid, and that the acid thus formed, if desired, is transferred to a salt thereof in a manner known per se .
Foretrukne forbindelser fåes ved å gå ut fra en forbindelse Preferred connections are obtained by starting from a connection
av formel II hvor R^ er p-klorfenyl, R^ er methyl og R^ er methoxy eller dimethylamino. of formula II where R^ is p-chlorophenyl, R^ is methyl and R^ is methoxy or dimethylamino.
De i det foreliggende beskrevne l-aroyl-3-indolyl-eddiksyrer fremstilles ved at en t-butylester i det annet trinn omdannes til den frie syre under passende reaksjonsbetingelser. Man har observert at 1-aroyl-substituenten lett hydrolyseres under betingelser som vanligvis brukes ved forsåpning av en ester til den frie syre. Av denne grunn må der utvises forsiktighet ved omdannelsen av 1-aroyl-3-indolyl-eddiksyre-esteren til de tilsvarende frie syrer. The 1-aroyl-3-indolyl acetic acids described herein are prepared by converting a t-butyl ester in the second step to the free acid under suitable reaction conditions. It has been observed that the 1-aroyl substituent is readily hydrolyzed under conditions commonly used in the saponification of an ester to the free acid. For this reason, care must be taken in the conversion of the 1-aroyl-3-indolyl-acetic acid ester to the corresponding free acids.
Den anti-inflammatoriske virkning av fremgangsmåteforbindelsene fremgår av en granulomahémmende prove som er utfort som folger: The anti-inflammatory effect of the process compounds is evident from a granuloma-inhibiting test which is carried out as follows:
Proven er én modifikasjon av den som er beskrevet av Meier The proof is one modification of the one described by Meier
og medarb. (Experientia 6 1950, *+69) • Den består hovedsakelig i implantering av steriliserte bomullspellets på rotter, fjernelse av pelletene efter 7 dager (systemprove) eller 5.dager (lokalprove), og bestemmelse av oknirigen av torrvekt av hver pellet. and collaborators (Experientia 6 1950, *+69) • It consists mainly in the implantation of sterilized cotton pellets on rats, the removal of the pellets after 7 days (system sample) or 5 days (local sample), and determination of the oknirigen of dry weight of each pellet.
Den: opprinnelige vekt av pelletene varierte fra forsok til forsok,.men innen et og samme forsok var alle innen en toleranse på + 1 mg. To pellets ble inrifort i hvert dyr., en på hver side av bukhulen. Når lokalvirkningen av en forbindelse skulle studeres, ble forbindelsen anbragt på en pellet i et medium inneholdende fuktemiddel, mens mediet alene ble brukt på den annen pellet, slik at hvert dyr var sin egen kontroll. Ved systemprover utgjorde den gjennomsnittlige granuloma-torrvekt av de to prover i hvert dyr det individuelle resultat. Proveforbindelsene ble gitt oralt.en gang daglig ved innforing i maven med sonde. The: initial weight of the pellets varied from trial to trial, but within one and the same trial all were within a tolerance of + 1 mg. Two pellets were injected into each animal, one on each side of the abdominal cavity. When the local effect of a compound was to be studied, the compound was placed on a pellet in a medium containing a wetting agent, while the medium alone was used on the other pellet, so that each animal was its own control. In the case of systemic samples, the average granuloma dry weight of the two samples in each animal constituted the individual result. The test compounds were given orally once a day by insertion into the stomach with a probe.
Ved alle forsok ble anvendt Holtzman-hanrotter over legemsvekt ca. 125 - 175 g. Aktiviteten ble uttrykt ved tallene 1 - h med folg-ende betydning: In all experiments, male Holtzman rats over a body weight of approx. 125 - 175 g. The activity was expressed by the numbers 1 - h with the following meaning:
1 omtrent så god som acetylsalicylsyre 1 about as good as acetylsalicylic acid
2 " " " " fenylbutazon 2 " " " " phenylbutazone
3 10 - 25 ganger så god som fenylbutazon 3 10 - 25 times as good as phenylbutazone
h 50 -100 " " " " " h 50 -100 " " " " "
De anvendte forbindelser og deres aktivitet fremgår av folg-ende tabell. The compounds used and their activity are shown in the following table.
Eksempel Example
Trinn 1 Step 1
^-,38 g t-butyl-l-p-klorbenzoyl-2-methyl-5-me'thoxy-3-indolyl-glyoxylat opplbses i 50 ml torr dioxan og hydrogeneres ved 30°C under et trykk på lh kg/cm 2 under anvendelse av 1,0 g palladium-p<å>o-carbon-katalysator med 10$ palladium. Hydrogeneringen er fullfort efter 8 tiimer. ^-.38 g of t-butyl-1-p-chlorobenzoyl-2-methyl-5-methoxy-3-indolyl-glyoxylate are dissolved in 50 ml of dry dioxane and hydrogenated at 30°C under a pressure of lh kg/cm 2 under using 1.0 g of palladium p<å>o carbon catalyst with 10% palladium. The hydrogenation is complete after 8 hours.
Katalysatoren frafiltreres derpå og filtratet inndampes, hvor-ved man.får et oljeaktig stoff. Dette residuum omkrystalliseres fra 25 ml hexan. Man får t-butyl-l-(p-klorbenzoyl)-2-methyl-5-methoxy-3-indolyl-acetat. The catalyst is then filtered off and the filtrate is evaporated, whereby an oily substance is obtained. This residue is recrystallized from 25 ml of hexane. t-Butyl-1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl-acetate is obtained.
Trinn 2 Step 2
300 ml p-toluensulfonsyremonohydrat (1,0 g) tilsettes til benzen som inneholder t-butyl-l-(p-klorbenzoyl)-2-methyl-5-methoxy-3-indolylacetat (0,03 mol), og den erholdte blanding oppvarmes under tilbakelopskjoling og omroring i nitrogenatmosfære i ^0 minutter. Herunder utvikles der 665 ml isobutylen (teoretisk 672 ml ). Reak-sjonsblandingen fortynnes med 200 ml benzen ved en temperatur på 300 ml of p-toluenesulfonic acid monohydrate (1.0 g) is added to benzene containing t-butyl-1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl acetate (0.03 mol), and the resulting mixture heated under reflux and stirring in a nitrogen atmosphere for ^0 minutes. Below this, 665 ml of isobutylene is developed (theoretically 672 ml). The reaction mixture is diluted with 200 ml of benzene at a temperature of
55 - 60°C og vaskes med varmt vann ved 60 - 65°C til en pH-verdi 55 - 60°C and washed with hot water at 60 - 65°C to a pH value
av k - 5. Den varme opplosning i benzen (temperatur 60 - 65°C) befries for vann med natriumsulfat og avfarves ved tilsetning av 1,0 g Darco G-60. Oppløsningen filtreres derpå i varm tilstand og inndampes til et volum på ca. 50 - 75 ml. Derefter avkjoles bland-ingen til 10°C, og man lar den henstå i h - 5' timer. Den herved erholdte urene l-(p-klorbenzoyl)-2-methyl-5-methoxy-3-indolyleddiksyre frafiltreres, vaskes to ganger med 5 ml av en blanding av benzen og .petrolether (1:1), derpå to ganger med 10 ml petrolether og torres i vakuum ved 25°C. Produktets vekt er 9,7 g, (benzensolvat) sm.p. 110 - 115°C. of k - 5. The hot solution in benzene (temperature 60 - 65°C) is freed from water with sodium sulfate and decolorized by adding 1.0 g of Darco G-60. The solution is then filtered while hot and evaporated to a volume of approx. 50 - 75 ml. The mixture is then cooled to 10°C, and left to stand for 1-5 hours. The impure 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid thus obtained is filtered off, washed twice with 5 ml of a mixture of benzene and petroleum ether (1:1), then twice with 10 ml petroleum ether and dried in vacuum at 25°C. The weight of the product is 9.7 g, (benzene solvate) m.p. 110 - 115°C.
9,7 g av dette råprodukt opploses i 38,8 ml t-butanol ved 70°C. Den erholdte opplosning filtreres og tilsettes i varm tilstand (60 - 70°C) 38,8 ml cyclohexan. Oppløsningen avkjoles til 10°C, hvorpå man lar den henstå i 1 time. Produktet frafiltreres så, vaskes to ganger med h ml av en kold blanding av t-butanol og cyclohexan (1:1) og derpå to ganger med 10 ml petrolether. Det torres derpå i vakuum ved 80°C i nitrogenatmosfære. Det erholdte produkt er 1-(p-klorbenzoyl)-2-methyl-5-methoxy-3-indolyl-eddiksyre med smeltep\inkt 153 - 154°C. 9.7 g of this crude product are dissolved in 38.8 ml of t-butanol at 70°C. The solution obtained is filtered and 38.8 ml of cyclohexane are added in a warm state (60 - 70°C). The solution is cooled to 10°C, after which it is allowed to stand for 1 hour. The product is then filtered off, washed twice with 10 ml of a cold mixture of t-butanol and cyclohexane (1:1) and then twice with 10 ml of petroleum ether. It is then dried in a vacuum at 80°C in a nitrogen atmosphere. The product obtained is 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl-acetic acid with a melting point of 153 - 154°C.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08123327A GB2103482B (en) | 1981-07-30 | 1981-07-30 | A sealing system for use on an offshore platform |
Publications (3)
Publication Number | Publication Date |
---|---|
NO822594L NO822594L (en) | 1983-01-31 |
NO163148B true NO163148B (en) | 1990-01-02 |
NO163148C NO163148C (en) | 1990-04-11 |
Family
ID=10523569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO822594A NO163148C (en) | 1981-07-30 | 1982-07-28 | PROCEDURE FOR PLANNING A SEALING SYSTEM ON A OFFSHOREBORE PLATFORM. |
Country Status (5)
Country | Link |
---|---|
CA (1) | CA1178813A (en) |
DK (1) | DK161983C (en) |
GB (1) | GB2103482B (en) |
NL (1) | NL8202795A (en) |
NO (1) | NO163148C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10422456B2 (en) | 2012-12-07 | 2019-09-24 | Apl Technology As | Tube connector for detachably connecting two connector parts for gas-tight connecting of riser tubes to vessels |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019912A1 (en) * | 1992-04-02 | 1993-10-14 | Akro Fireguard Products, Inc. | Aircraft fuselage flame barrier |
-
1981
- 1981-07-30 GB GB08123327A patent/GB2103482B/en not_active Expired
-
1982
- 1982-07-06 CA CA000406746A patent/CA1178813A/en not_active Expired
- 1982-07-09 NL NL8202795A patent/NL8202795A/en not_active Application Discontinuation
- 1982-07-28 NO NO822594A patent/NO163148C/en unknown
- 1982-07-28 DK DK336582A patent/DK161983C/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10422456B2 (en) | 2012-12-07 | 2019-09-24 | Apl Technology As | Tube connector for detachably connecting two connector parts for gas-tight connecting of riser tubes to vessels |
Also Published As
Publication number | Publication date |
---|---|
DK336582A (en) | 1983-01-31 |
NO822594L (en) | 1983-01-31 |
GB2103482A (en) | 1983-02-23 |
CA1178813A (en) | 1984-12-04 |
NL8202795A (en) | 1983-02-16 |
NO163148C (en) | 1990-04-11 |
GB2103482B (en) | 1985-05-09 |
DK161983B (en) | 1991-09-02 |
DK161983C (en) | 1992-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3654349A (en) | Substituted indenyl acetic acids | |
US4342776A (en) | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | |
NO162189B (en) | ANALOGY PROCEDURE TE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOPYRIDINES. | |
US4309442A (en) | Method for controlling fertility in mammals | |
NO883146L (en) | ANTI-INFLAMMATORALLY ACTIVE ARYLET DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION. | |
US4820827A (en) | 2,3-diaryl-5-bromothiophene compounds of use for the treatment of inflammaton and dysmenorrhea | |
US20020107248A1 (en) | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | |
EP0219961B1 (en) | Irreversible dopamine-b-hydroxylase inhibitors | |
US4069337A (en) | 2-substituted-indole-1-lower-alkanecarboxamides having anti-secretory or anti-ulcer activity | |
IE52444B1 (en) | New derivatives of phenyl aliphatic carboxylic acids,their preparation,their use as medicaments and compositions containing them | |
NO163148B (en) | PROCEDURE FOR PLANNING A SEALING SYSTEM ON A OFFSHOREBORE PLATFORM. | |
NO143735B (en) | PULLERTANORDNING. | |
US4459404A (en) | Amides of retinoic acids with 5-amino tetrazole | |
JPS63253070A (en) | Inidazole derivative | |
LU84860A1 (en) | NEW PYRAZOLO (1,5-A) PYRIDINE DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
DE2535799C3 (en) | N'- [1 - (p-Chlorobenzoyl) -5-methoxy-2-methyl-3indolyl-acetoxy-alkyl] -N- (N-benzoyl-N'JS'-di-n-propyl-DL-isoglutaminyloxy-alkyD-piperazine and preparations containing inflammation and joint affection inhibiting preparations | |
DE69015072T2 (en) | Naphthalene and tetrahydronaphthalene gem diphosphonate derivatives. | |
US2954400A (en) | alpha-indanoxybutyric acid derivatives | |
US4219668A (en) | 4-Hydroxy,4-biphenylbutyric acid | |
JP3056245B2 (en) | Phenyl sulfone derivative | |
US4867737A (en) | Derivatives of 4-phenyl-4-oxo-2-butenoic acid their preparation process, their use as medicaments and compositions containing them | |
NO121838B (en) | ||
NO122372B (en) | ||
US4156016A (en) | Indole compounds and process for their preparation | |
US4110465A (en) | 7-amino and 7-alkanoylamino 2-oxo-3-phenylindolines |